Vitiligo is the most common chronic disorder of skin discoloration, which affects about 0.5% of the world's population.
The Treatments For Vitiligo:
- UVB ( 290-320 Nm)
- Narrow Band-UVB (311 Nm)
- VISIBLE LIGHT & A Wavelength Of 633 Nm
- Excimer Laser Phototherapy (308nm)
- Discoloration Of Existing Melanin
- Calcineurin Inhibitors: Tacrolimus & Pimecrolimus
- Corticosteroids (Topical, Endoscopic And Systematically)
Guidelines of treatment of vitiligo by the European Academy of Dermatology
The most effective treatment of vitiligo include phototherapy and combination therapy, according to the most recent guidelines from the scientific group writing Vitiliho European Task Force (VETF), which have been accepted for publication and published in a reputable magazine British Hournal of Dermatology.
The European Academy of Dermatology and Venereology (European Academy of Dermatology and Venereology) collaborated with the VETF for the development of new data and guidelines for vitiligo.
Vitiligo is a disease that has no definitive and fully effective treatments. However, phototherapy and combination therapies are the most effective treatments.
The treatment should be stopped further development of the lesions and to offer full or almost full επαναμελάγχρωση that is considered satisfactory for the patient.
Worldwide, the prevalence of vitiligo is 0.5%, with no differentiation at specific age groups, races or gender.
The causes and παθοφυσιολογικοί mechanisms governing the vitiligo is still very little understood and remain poorly specified. This is the main reason that slows down the progress in diagnosis and treatment.
Recommended the following principles for the treatment of segmental vitiligo or
of a limited non-incremental (for less than 2%-3% of body surface):
- First-Line Therapy Is The Avoidance Of Factors That Can Be Put Into The Mechanisms That Can Develop Vitiligo And The Use Of Topical Agents Such As Corticosteroids Or Calcineurin Inhibitors.
- Second-Line Therapy Could Be The Localized Narrow-Spectrum Ultraviolet B (Nb-UVB 311nm), Preferably With Excimer Μονογχρωματικό Light Or Laser.
- Third-Line Therapy In Patients With Aesthetically Unsatisfactory Επαναμελάγχρωση In Visible Areas After Treatment Of A First-Or Second-Line, Are The Surgical Techniques.
Recommended The Following Principles For The Treatment Of Non-Segmental Vitiligo:
- First-Line Therapy Is The Avoidance Of Factors That Can Be Put Into The Mechanisms That Can Develop Vitiligo Or Aggravating Factors, And The Stabilization Of The Patient By Treatment With Nb-UVB For 3 Months At Least. Patients Who Respond To Nb-UVB Should Continue The Treatment For 9 Months Or More. An Additional Consideration Is The Combination Of Local Therapy UVB With Systemic Or Local Treatments.
- Second-Line therapy For Patients With Rapidly Progressive Disease Or Lack of Stabilisation With Nb-UVB, it Is The systemic Corticosteroids, Minipulse Therapy For 3-4 Months, Or Immunosuppressants.
- Third-Line Therapy Is The Transplantation Of Areas That Do Not Respond To Previous Treatment, Particularly Those Areas That Are Important Aesthetically. The Koebner Phenomenon Or Development Of Vitiligo Re In An Area Of Skin That Had Never Been Affected Before, In Skin Injury, Can Reduce The Durability Of The Graft. The Cuttings Are Not Indicated On The Back Of The Hand And In Similar Areas.
- Treatment Of A Fourth Line For Extensive Vitiligo (Covering More Than 50% Of The Body Surface), Which Is Resistant To Treatment, Or Is Visibly Apparent Is The Discoloration Using Hydroquinone Monobenzyl Ether Or 4-Methoxyphenol In Monotherapy Or In Combination With Q-Switched Laser.